Evidence map›Paper›PMID 31260447›Full record

ArticlePloS one2019

An one-pot two-step automated synthesis of [18F]T807 injection, its biodistribution in mice and monkeys, and a preliminary study in humans.

Ya-Yao Huang, Ming-Jang Chiu, Ruoh-Fang Yen, Chia-Ling Tsai, Hao-Yu Hsieh, Ching-Hung Chiu, Chi-Han Wu, Ling-Wei Hsin, Kai-Yuan Tzen, Cheng-Yi Cheng and 2 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in PloS one, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.3field-weighted citation impact, top 47% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. IntegratedFrontiers in aging neuroscience · 2021
    Article
  3. Automated production of [American journal of nuclear medicine and molecular imaging · 2021
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 1 country.

Ya-Yao HuangPET Center, Department of Nuclear Medicine, National Taiwan University Hospital, Taipei, Taiwan.ORCID 0000-0002-3460-7922
Ming-Jang ChiuMolecular Imaging Center, National Taiwan University, Taipei, Taiwan.
Ruoh-Fang YenPET Center, Department of Nuclear Medicine, National Taiwan University Hospital, Taipei, Taiwan.
Chia-Ling TsaiPET Center, Department of Nuclear Medicine, National Taiwan University Hospital, Taipei, Taiwan.
Hao-Yu HsiehSchool of Pharmacy, College of Medicine, National Taiwan University, Zhongzheng Dist., Taipei, Taiwan.
Ching-Hung ChiuPET Center, Department of Nuclear Medicine, National Taiwan University Hospital, Taipei, Taiwan.
Chi-Han WuMolecular Imaging Center, National Taiwan University, Taipei, Taiwan.
Ling-Wei HsinMolecular Imaging Center, National Taiwan University, Taipei, Taiwan.
Kai-Yuan TzenPET Center, Department of Nuclear Medicine, National Taiwan University Hospital, Taipei, Taiwan.
Cheng-Yi ChengPET Center, Department of Nuclear Medicine, Tri-Service General Hospital, Neihu, Taipei, Taiwan.
Kuo-Hsing MaDepartment of Biology and Anatomy, National Defense Medical Center, Taipei, Taiwan.
Chyng-Yann ShiuePET Center, Department of Nuclear Medicine, National Taiwan University Hospital, Taipei, Taiwan.ORCID 0000-0002-8548-8871
National Taiwan University · TWNational Taiwan University Hospital · TWTri-Service General Hospital · TWNational Defense Medical Center · TW

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

[18F]T807 is a potent tau protein imaging agent. In order to fulfill the demand from preclinical and clinical studies, we developed an automated one-pot two-step synthesis of this potent tau imaging agent and studied its stability, and dosimetry in mice and monkeys. We also conducted a preliminary study of this imaging agent in humans. Using this one-pot two-step method, the radiochemical yield (RCY) of [18F]T807 was 20.5 ± 6.1% (n = 15) at the end of bombardment (EOB) in a synthesis time of 70±5 min. The chemical and radiochemical purities were >90% and the specific activities were 151 ± 52 GBq/μmol. The quality of [18F]T807 synthesized by this method met the U.S. Pharmacopoeia (USP) criteria. The stability test showed that the [18F]T807 injection was stable at room temperature for up to 4 h after the end of synthesis (EOS). The estimated effective dose of the [18F]T807 injection extrapolated from monkeys was 19 μSv/MBq (n = 2), while the estimated effective doses of the [18F]T807 injection extrapolated from fasted and non-fasted mice were 123 ± 27 (n = 3) and 94 ± 19 (n = 4) μSv/MBq, respectively. This one-pot two-step automated method produced the [18F]T807 injection with high reproducibility and high quality. PET imaging and radiation dosimetry evaluation in mice and Formosan rock monkeys suggested that the [18F]T807 injection synthesized by this method is suitable for use in human PET imaging studies. Thus, this method could fulfill the demand for the [18F]T807 injection in both preclinical and clinical studies of tauopathies, especially for nearby study sites without cyclotrons.

Indexed as

Alzheimer DiseaseAnimalsBiological AvailabilityCarbolinesContrast MediaDrug Evaluation, PreclinicalGene ExpressionHaplorhiniHumansInjections, IntravenousMacacaMaleMiceMice, Inbred ICRMiddle AgedPositron-Emission Tomography7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indoleCarbolinesContrast MediaRadiopharmaceuticalstau Proteins

Identifiers

PMID31260447
PMCPMC6602418
OpenAlexW2955224299

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.